In the latest version of
ChEMBL (version 21), the approved drugs data freezes December 2015. So there are 1,967 approved (or marketed) drugs (development phase: 4) in a large pool of 11,222 ChEMBL drugs. I thought I should peek into this data and create some quick views.
ChEMBL drugs by development phase
As per the first approval dates provided, here is how the timeline of drug approval looks like. The first ever drug approval dates back to 1939. A huge number of the marketed drugs were approved in the year 1982 followed by 1996 and 2015. Although there is no clear trend, the overall number of approvals increased till 1996 after which the number decreased and has improved in the last couple of years.
Timeline of drug approval
A total of 1,646 of all the approved drugs have an
ATC code assigned. The most prominent anatomical classes (first-level ATC) are N (284), A (275), C (229) and L (223). It is interesting to see more number of systemic hormonal preparations (class H) than anti-parasitic and insecticide drugs (class P). One should note that a drug could belong to more than one anatomical class depending on the indications it is used for.
Distribution of drugs in different first-level ATC classes
Increasing evidences state that drugs interact with more than one biological target to elicit biological effects, supporting the polypharmacology paradigm. It will be interesting to see how this looks for the approved drugs. For this post, I only chose drug-target interactions in ChEMBL for which mechanism of action is known. There are two aspects of promiscuity that I would like to present here: drug promiscuity and target promiscuity. While the first is about the number of targets a drug interacts with, the latter is about the number of drugs that interact with a single target.
Drug promiscuity trend
Target promiscuity trend
It must be noted that the drug promiscuity and target promiscuity picture would be completely different when we consider activity information from bioassays. But considering this particular knowledge, a majority of biological targets still have only approved drug which interacts with them. This means that there is lot of scope for experimental drugs to explore these targets. Here are the top 10 targets interacting with most number of drugs and the first ever drug approved.
Top 10 targets by number of interacting drugs
A lot more can be understood from the data if deeply analysed. For instance one can see which molecular frameworks (scaffolds and cyclic skeletons) are prevalent among the approved drugs in comparison to drugs in other developmental phases (3, 2, and 1).